Genzyme
Executive Summary
Biotech firm begins previously announced spin off of genetic testing subsidiary IG Labs via a 1.9 mil. share public offering at $7.50 per share on May 3. Upon completion of the offering, Genzyme will own approximately 56% of IG Labs. Oppenheimer & Company is the managing underwriter.